Polycystic ovarian syndrome and thrombophilia

Human Reproduction

Volumn 17, Issue 2, 2002, Pages 314-319

  Tsanadis, G ^a   Vartholomatos, G ^a   Korkontzelos, I ^a   Avgoustatos, F ^a   Kakosimos, G ^a   Sotiriadis, A ^a   Tatsioni, A ^a   Eleftheriou, A ^a   Lolis, D ^a  

^a UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

Author keywords

Antithrombin III; Factor V Leiden; Methylene tetrahydrofolate reductase; PCOS; Thrombophilia

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ACTIVATED PROTEIN C; ANTITHROMBIN III; BLOOD CLOTTING FACTOR 5 LEIDEN; HOMOCYSTEINE; INSULIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN C; PROTEIN S; PROTHROMBIN;

ANTITHROMBIN III DEFICIENCY; ARTICLE; BLOOD CLOTTING FACTOR 5 DEFICIENCY; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE PREDISPOSITION; FEMALE; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HETEROZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MOLECULAR DYNAMICS; OVARY POLYCYSTIC DISEASE; POPULATION RESEARCH; PREVALENCE; PROTEIN BLOOD LEVEL; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; SPONTANEOUS ABORTION; STATISTICAL ANALYSIS; THROMBOPHILIA;

FALLOPIA;

EID: 0036183099     PISSN: 02681161     EISSN: None     Source Type: Journal    
DOI: 10.1093/humrep/17.2.314     Document Type: Article

References (42)

1. Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism
2. The mutation Ala677→Val in the methylene tetrahydrofolate reductase gene: A risk factor for arterial disease and venous thrombosis
3. Are women with polycystic ovary syndrome resistant to activated protein C?
4. Molecular risk factors for thrombosis
5. Protein C deficiency and venous thrombosis the search for the second genetic defect
6. Inherited thrombophilia and pregnancy loss
7. A methylenetetrahydrofate reductase polymorphism and the risk of colorectal cancer
8. 506 to Gln mutation in factor V as a pathogenic risk factor for venous thrombosis
9. Blood coagulation
10. Interaction between hyperhomocysteinemia and inherited thrombophilic factors in venous thromboembolism
11. Therapeutic effects of metformin in insulin resistance and hyperandrogenism in polycystic ovary syndrome
12. Thermolabile 5,10-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia
13. Factor V Leiden and prothrombin G20210A mutations, but not methylenetetrahydrofolate reductase C677T, are associated with recurrent miscarriage
14. The genetic basis of polycystic ovarian syndrome
15. A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase
16. Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with the polycystic ovary syndrome
17. Plasminogen activator inhibitor activity: An independent risk factor for the high miscarriage rate during pregnancy in patients with polycystic ovary syndrome
18. Polycystic ovary syndrome, infertility, familial thrombophilia, familial hypofibrinolysis, recurrent loss of in vitro fertilized embryos, and miscarriage
19. Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: A pilot study
20. Hyperhomocysteinemia and thrombosis
21. The 20210A allele of the prothrombin gene is a common risk factor among Swedish outpatients with verified deep venous thrombosis
22. Prevalence of polycystic ovary syndrome (PCOS) in first-degree relatives of patients with PCOS
23. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: A prospective study
24. Increased frequency of genetic thrombophilia in women with complications of pregnancy
25. Factor V Leiden in Greek thrombophilic patients: Relationship with activated protein C resistance test and levels of thrombin-antithrombin complex and prothrombin fragment 1 + 2
26. The methylenetetrahydrofolate reductase TT677 genotype is associated with venous thrombosis independently of the coexistence of the FV Leiden and the prothrombin A20210 mutation
27. Protein C and S deficiency
28. A common genetic variation in the 3′ untranslated region of the prothrombin gene is associated with elevated plasma levels and an increase in venous thrombosis
29. Polycystic ovaries and recurrent miscarriage: A reappraisal
30. Factor V Leiden and acquired activated protein C resistance among 1000 women with reccurent miscarriage
31. Thrombosis series: Venous thrombosis: A multicausal disease
32. Genetic modulations of homocystinemia
33. Insulin-sensitizing agents in polycystic ovary syndrome
34. Biological and environmental determinants of plasma hocysteine
35. Worldwide distribution of a common methylenetetrahydrofolate reductase mutation
36. Are factor V Leiden carriers who use oral contraceptives at extreme risk for venous thromboembolism
37. Thirty-seven candidate genes for polycystic ovary syndrome: Strongest evidence for linkage is with folistatin
38. Metformin therapy is associated with decreased plasma plasminogen activator inhibitor-1, lipoprotein (a) and immunoreactive insulin levels in patients with the polycystic ovary syndrome
39. Hereditary and acquired antithrombin deficiency
40. Homocysteine and venous thrombosis: Outline of a vitamin intervention trial
41. Familial thrombophilia. The scientific rationale for thromboprophylaxis in recurrent pregnancy loss?
42. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C